| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/10/2001 | EP1066310A1 Neokine protein and nucleic acid molecules and uses therefor |
| 01/10/2001 | EP1066286A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 01/10/2001 | EP1066271A1 Thiocarboxamide derivatives and their use as inhibitors of alpha-4 integrins |
| 01/10/2001 | EP1066265A1 Pyridazinone hydrochloride compound and method for producing the same |
| 01/10/2001 | EP1066257A2 Heterocylic classes of compounds for the modulating tyrosine protein kinase |
| 01/10/2001 | EP1066060A2 Mesenchymal stem cells as immunosuppressants |
| 01/10/2001 | EP1066058A1 Methods and means for the treatment of immune related diseases |
| 01/10/2001 | EP1066055A1 Adjuvant-containing vaccines |
| 01/10/2001 | EP1066054A2 Use of active p40 conjugates for nasal delivery |
| 01/10/2001 | EP1066052A2 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 01/10/2001 | EP1066050A2 Application of hsp70 proteins |
| 01/10/2001 | EP1066043A2 Materials and methods relating to the treatment of conditions involving mast cells, basophils and eosinophils |
| 01/10/2001 | CN1279688A Viral clearance process |
| 01/10/2001 | CN1279686A Inhibitors of nucleoside metabolism |
| 01/10/2001 | CN1279682A bicyclic kinase inhibitors |
| 01/10/2001 | CN1279681A Piperidylaminomethyltrifluoromethyl cyclic ether compound as p substance antagonist |
| 01/10/2001 | CN1279676A Pseudopolymorphic forms of z-[2-[4-(bis(4-fluorophenyl)methyl]-1-piperazinyl]ethozy] acetic and dihydrochloride |
| 01/10/2001 | CN1279672A Pyridazine derivatives and drugs containing the same as the active ingredient |
| 01/10/2001 | CN1279612A Modulation of immune responses |
| 01/10/2001 | CN1279606A Use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 01/10/2001 | CN1279110A In-colon release-controlled thymopeptide capsule and process for extracting and separating thymopeptide |
| 01/10/2001 | CN1279108A Chinese medicine for making body strouger and delaying sanility |
| 01/10/2001 | CN1060472C Hydroxamic acid derivatives with tricylic substitution, their preparing methods, medicines containing them and uses thereof |
| 01/10/2001 | CN1060465C Antianaphylaxis, anti-asthma and anti-inflammatory new medicine |
| 01/10/2001 | CN1060384C Oral liquid against senility and preparation thereof |
| 01/10/2001 | CN1060357C Pellet with immunity detoxication function and preparation method |
| 01/09/2001 | US6172193 Escape mutant of the surface antigen of hepatitis B virus |
| 01/09/2001 | US6172116 Use of aminoadamantane compounds as immunoregulators |
| 01/09/2001 | US6172107 Mycophenolate salt disintegrates selectively in intestines |
| 01/09/2001 | US6172096 Administering 4-pyrazolylbenzenesulfonamide derivatives to treat autoimmune diseases |
| 01/09/2001 | US6172080 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/09/2001 | US6172068 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 01/09/2001 | US6172060 Therapy for sexual disorders |
| 01/09/2001 | US6172048 Composition containing nucleic acids, preparation and uses |
| 01/09/2001 | US6172042 Synthetic peptides that inhibit IL-6 activity |
| 01/09/2001 | US6172041 Nervous system disorders |
| 01/09/2001 | US6171830 Efficient purification of mycolic acids, salts or derivatives by dissolving mixture in bi-phasic solvent, subjecting to countercurrent distribution separation with sufficient cycles, then recovering |
| 01/09/2001 | US6171803 Drug screening for allergy treatments by engineering expression of alpha, beta, and gamma subunits of receptor in host cell, incubating with candidate inhibitor, and analyzing for cell expression or cell activation |
| 01/09/2001 | US6171799 Immunoassay detection of a v beta 5.3 t cell by contacting tissue sample with a monoclonal antibody which reacts to variable region of beta chain of the receptor; diagnosis and treatment of rheumatoid arthritis |
| 01/09/2001 | US6171795 Nucleic acid ligands to CD40ligand |
| 01/09/2001 | US6171790 Human protease associated proteins |
| 01/09/2001 | US6171783 Detecting parainfluenza virus-3 and respiratory syncytial virus infection by using fusion protein of antigenic proteins from both viruses |
| 01/09/2001 | US6171781 NF-AT polypeptides and polynucleotides |
| 01/09/2001 | US6171618 Combination dosage form comprising cetirizine and pseudoephedrine |
| 01/09/2001 | US6171603 Treating skin, hair, cardiovascular, autoimmune and vision disorders; administering as anticarcinogenic, antidepressant,antiinflammatory, and antiacne agents |
| 01/09/2001 | US6171597 Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
| 01/09/2001 | US6171591 Recombinant nodavirus compositions and methods |
| 01/09/2001 | US6171590 Treatment and prevention of inflammatory responses. |
| 01/09/2001 | CA2204640C Conjugates of bdnf and nt-3 with a water-soluble polymer |
| 01/04/2001 | WO2001000880A2 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
| 01/04/2001 | WO2001000830A1 Sgip peptides |
| 01/04/2001 | WO2001000828A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | WO2001000824A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 01/04/2001 | WO2001000812A2 22012, a novel human carboxypeptidase |
| 01/04/2001 | WO2001000658A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/04/2001 | WO2001000655A2 Therapeutic peptides derived from subsequences of bpi |
| 01/04/2001 | WO2001000622A1 Prodrugs of carbamate inhibitors of impdh |
| 01/04/2001 | WO2001000587A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 01/04/2001 | WO2001000585A1 Pyrazolidinol compounds |
| 01/04/2001 | WO2001000237A1 Synthetic peptide immunogens and antibodies thereto |
| 01/04/2001 | WO2001000235A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | WO2001000233A1 Vaccine compositions using antigens encapsulated within alginate microspheres for oral administration and preparation process thereof |
| 01/04/2001 | WO2001000228A1 Method for preventing tumoral growth |
| 01/04/2001 | WO2001000214A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000213A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000210A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | WO2001000207A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000206A1 Vla-4 inhibitor compounds |
| 01/04/2001 | WO2001000145A1 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 01/04/2001 | WO2001000139A1 Topical formulations comprising skin penetration agents and the use thereof |
| 01/04/2001 | WO2001000047A1 Prophylactic dietary supplement based on milk |
| 01/04/2001 | WO2000060082A3 Vesicle associated proteins |
| 01/04/2001 | WO2000059449A3 Purine derivatives having phosphodiesterase iv inhibition activity |
| 01/04/2001 | WO2000056405A3 Human tumor necrosis factor receptor-like 2 |
| 01/04/2001 | WO2000056358A3 Vaccine against streptococcus pneumoniae capsular polysaccharides |
| 01/04/2001 | WO2000054797A3 Pharmaceutical compositions comprising tgf-beta |
| 01/04/2001 | WO2000039302A3 Improved expression of hiv polypeptides and production of virus-like particles |
| 01/04/2001 | DE19930557A1 Hydrate von Ciprofloxacin und Verfahren zu ihrer Herstellung Hydrates of ciprofloxacin and processes for their preparation |
| 01/04/2001 | DE19930327A1 Inducing an immune response, e.g. to cancer cells or pathogens, comprises temporarily implanting an antigen in a housing that is impermeable to the antigen but permeable to the patient's antibodies |
| 01/04/2001 | CA2383546A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2380873A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | CA2378221A1 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377200A1 Pyrazolidinol compounds |
| 01/04/2001 | CA2376957A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376951A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376920A1 Method for preventing tumoral growth |
| 01/04/2001 | CA2376914A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | CA2375952A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | CA2369308A1 Vla-4 inhibitor compounds |
| 01/04/2001 | CA2365341A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/04/2001 | CA2339404A1 Synthetic peptide immunogens and antibodies thereto |
| 01/03/2001 | EP1065212A2 Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines |
| 01/03/2001 | EP1064947A1 In ovo vaccination of 1 type marek's disease virus |
| 01/03/2001 | EP1064942A1 Sustained release preparations |
| 01/03/2001 | EP1064551A1 Development of human monoclonal antibodies and uses thereof |
| 01/03/2001 | EP1064403A1 Antisense modulation of pecam-1 |
| 01/03/2001 | EP1064402A1 Antisense modulation of lfa-3 |
| 01/03/2001 | EP1064390A1 Enhanced anti-tumor immunity |
| 01/03/2001 | EP1064388A1 Human casb12 polypeptide, a serine protease |